FDAnews
www.fdanews.com/articles/75012-medigene-q2-net-loss-5-4-mln-eur-vs-loss-2-7-mln-reiterates-fy-guidance

MEDIGENE Q2 NET LOSS 5.4 MLN EUR VS LOSS 2.7 MLN; REITERATES FY GUIDANCE

August 4, 2005

MediGene AG said its second quarter net loss widened to 5.4 mln eur from a loss of 2.7 mln the year earlier, due to higher milestone payments last year; while reiterating its full-year guidance for a net loss below 10 mln eur. The German-American biotech company said sales in the quarter fell to 1.1 mln from 4.9 mln. Medigene said the sales were generated almost entirely by the commercialisation of its cancer drug Eligard, through product sales, license fees and milestone payments received from MediGene's marketing partner Astellas Pharma Europe Ltd.

Forbes (http://www.forbes.com/business/feeds/afx/2005/08/03/afx2169094.html)